<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366971">
  <stage>Registered</stage>
  <submitdate>8/09/2014</submitdate>
  <approvaldate>15/09/2014</approvaldate>
  <actrnumber>ACTRN12614000991617</actrnumber>
  <trial_identification>
    <studytitle>An investigation of the effects of intranasal oxytocin spray on socio-emotional brain regions in participants with Body Dysmorphic Disorder.</studytitle>
    <scientifictitle>An investigation of the effects of intranasal oxytocin spray on socio-emotional brain regions in participants with Body Dysmorphic Disorder.</scientifictitle>
    <utrn>U1111-1160-8784 </utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Body Dysmorphic Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Two acute treatment (24 IU each) conditions including; a) intranasal placebo, and b) intranasal oxytocin (Syntocinon, Novartis, Switzerland). The two treatment conditions will be separated by a minimum of 1 week (washout period). The nasal sprays will be administered 50 mins prior to the functional magnetic resonance (fMRI) protocol. The fMRI protocol will be one hour in duration and involve showing participants a brief task involving pictures of human faces expressing different emotions. The fMRI protocol will also involve taking structural, resting state and diffusion tensor imaging (DTI) images of the brain while the participant is not engaged in a task. </interventions>
    <comparator>Placebo, a saline solution without the active (peptide) ingredient.
Healthy controls will be used in comparisons to the Body Dysmorphic Disorder (BDD) patients.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Functional MRI (fMRI) data will be collected in response to an emotional face expression task. The fMRI data will be compared within the patient (Body Dysmorphic Disorder) group for differences in brain response (e.g., in the amygdala) between placebo and oxytocin conditions.</outcome>
      <timepoint>The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Using the fMRI data, the patients with BDD will be compared to healthy controls on brain response (e.g., amygdala) under normal (placebo) conditions to see whether any differences in brain activity is present.

Using the DTI and structural MRI data, the whole-brain and white matter structure of the brains of patients with BDD will be examined in comparison to the healthy control group to see if any structural or white matter differences are present.</outcome>
      <timepoint>The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For Healthy controls: Right-handed; between the ages of 18-65 years; non-smoker and no drug/alcohol abuse; medication free; no neurological disorders, and no metal objects present in body (or which can't be removed or which is not MRI safe). Women who have not experienced menopause.
For Body Dysmorphic Disorder (BDD): As above plus a diagnosis of the disorder is required.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Clinically significant medical or neurological condition (other than BDD for the patients), significant head injury (or loss of consciousness from longer than 5 mins), presence of ferrous-containing metals within the body, inability to tolerate small enclosed spaces without anxiety.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/11/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>64</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Susan Rossell</primarysponsorname>
    <primarysponsoraddress>PO Box 218 
Swinburne University of Technology
Hawthorn VIC 3122</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Prof Susan Rossell's Research Initiative Scheme within the Faculty of Health, Arts and Design, Swinburne University of Technology, Melbourne, Australia.</fundingname>
      <fundingaddress>PO Box 218 
Hawthorn VIC 3122</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The overall aim of the current study is to examine the brain correlates of emotion recognition in patients with Body Dysmorphic Disorder using a double-blind placebo controlled intranasal oxytocin design and two MRI techniques involving fMRI and diffusion tensor imaging (DTI).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Melbourne (SVHM)</ethicname>
      <ethicaddress>41 Victoria Parade 
Fitzroy
VIC 3065</ethicaddress>
      <ethicapprovaldate />
      <hrec>HREC-D 089/14</hrec>
      <ethicsubmitdate>28/07/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Susan Rossell</name>
      <address>PO Box 218 
Brain and Psychological Sciences Research Institute (BPsyC)
Swinburne University of Technology
Hawthorn VIC 3122</address>
      <phone>+61 3 9214 8173</phone>
      <fax />
      <email>SRossell@SRossell.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Sally Grace</name>
      <address>400B Burwood Road, Level 2
Swinburne University of Technology
Hawthorn VIC 3122</address>
      <phone>+61392148415</phone>
      <fax />
      <email>sgrace@swin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Sally Grace</name>
      <address>400B Burwood Road, Level 2
Swinburne University of Technology
Hawthorn VIC 3122</address>
      <phone>+61392148415</phone>
      <fax />
      <email>sgrace@swin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Sally Grace</name>
      <address>400B Burwood Road, Level 2
Swinburne University of Technology
Hawthorn VIC 3122</address>
      <phone>61448025648</phone>
      <fax />
      <email>sgrace@swin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>